Research graph
References from Stepwise dual antiplatelet therapy de-escalation versus standard therapy for 12 months in patients with bifurcation lesions undergoing drug-coated balloon angioplasty: Insights from the REC-CAGEFREE II trial. Local targets link to admitted publications; unresolved targets remain external evidence.
2023 ESC guidelines for the management of acute coronary syndromes
10.1093/eurheartj/ehad191 · 2023 · External reference
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients
2017 · External reference
Single-antiplatelet treatment after coronary angioplasty with drug-coated balloon
10.1161/jaha.122.028413 · 2023 · External reference
Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group
10.1016/j.jcin.2020.02.043 · 2020 · External reference
Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial
10.1136/bmj-2024-082945 · 2025 · External reference
Drug-coated balloons for coronary bifurcation lesions
10.4244/eij-d-25-00201 · 2025 · External reference
Impact of local flow haemodynamics on atherosclerosis in coronary artery bifurcations
10.4244/eijv11sva4 · 2015 · External reference
Percutaneous coronary intervention of bifurcation lesions
10.4244/eij-d-21-01065 · 2022 · External reference
Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry
10.23736/s0031-0808.22.04604-3 · 2023 · External reference
Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: insights from the ULTRA-BIFURCAT registry
10.1016/j.ijcard.2025.133542 · 2025 · External reference
Benefit of extended dual antiplatelet therapy duration in acute coronary syndrome patients treated with drug eluting stents for coronary bifurcation lesions (from the BIFURCAT registry)
10.1016/j.amjcard.2021.07.005 · 2021 · External reference
Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the coronary bifurcation stenting registry II
10.1161/circinterventions.117.005849 · 2018 · External reference
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
10.1016/j.jacc.2016.03.513 · 2016 · External reference
10.1093/eurheartj/ehx419
10.1093/eurheartj/ehx419 · 2018 · External reference
Randomized evaluation of 5-month ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design
10.1186/s12872-024-03709-1 · 2024 · External reference
Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group
10.1007/s00392-013-0609-7 · 2013 · External reference
The win ratio approach for composite endpoints: practical guidance based on previous experience
10.1093/eurheartj/ehaa665 · 2020 · External reference
Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document
10.1161/circulationaha.117.029289 · 2018 · External reference
Fourth universal definition of myocardial infarction (2018)
10.1016/j.jacc.2018.08.1038 · 2018 · External reference
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
10.1161/circulationaha.110.009449 · 2011 · External reference
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use
10.1093/eurheartj/ehae647 · 2024 · External reference
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions
10.4244/eij-d-20-00885 · 2021 · External reference
Clinical outcome after percutaneous coronary intervention with drug-eluting stent in bifurcation and nonbifurcation lesions: a meta-analysis of 23981 patients
10.1097/mca.0000000000000847 · 2020 · External reference
The role of drug-coated balloons for coronary bifurcation management: results from the prospective EASTBOURNE-BIF study
10.23736/s2724-5683.23.06443-8 · 2024 · External reference
Sirolimus-eluting balloon with provisional stenting versus systematic drug-eluting stent implantation to treat de novo coronary lesions: a randomized, open-label, noninferiority trial
10.1161/circulationaha.126.079033 · 2026 · External reference
Drug-coated balloon angioplasty vs drug-eluting stents in noncomplex coronary bifurcation lesions: the REC-CAGEFREE I trial
10.1016/j.jcin.2026.02.009 · 2026 · External reference
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial
10.1016/s0140-6736(24)01594-0 · 2024 · External reference
Impact of prolonged dual antiplatelet therapy after bifurcation percutaneous coronary intervention in patients with high ischemic risk
10.1007/s40256-024-00657-1 · 2024 · External reference
Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: insight from GLOBAL LEADERS trial
2020 · External reference
Coronary vasomotion after treatment with drug-coated balloons or drug-eluting stents: a prospective, open-label, single-centre randomised trial
10.4244/eij-d-21-00636 · 2022 · External reference
Results from the international drug coated balloon registry for the treatment of bifurcations. Can a bifurcation be treated without stents?
10.1111/joic.12301 · 2016 · External reference
Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial
10.1007/s00392-015-0957-6 · 2016 · External reference
Treatment of coronary de novo bifurcation lesions with DCB only strategy
10.1007/s00392-014-0671-9 · 2014 · External reference
Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography
10.4244/eij-d-17-00794 · 2018 · External reference
Pathological evaluation of predictors for delayed endothelial coverage after currently available drug-eluting stent implantation in coronary arteries: impact of lesions with acute and chronic coronary syndromes
10.1016/j.ahj.2024.08.003 · 2024 · External reference
Is the axiom of balloon angioplasty, "the more you gain the more you lose," still true in the era of DCB with paclitaxel?
10.1016/j.carrev.2024.04.001 · 2024 · External reference
Drug-coated balloon-based strategy in real-world coronary bifurcation lesions: a retrospective comparative study
10.1016/j.carrev.2026.05.010 · 2026 · External reference
Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions
2014 · External reference
Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention
10.1016/j.jacc.2008.12.034 · 2009 · External reference
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial
10.1093/eurheartj/ehaf652 · 2026 · External reference
